NO20051423L - RNAi-prober som malsoker cancer-relaterte proteiner - Google Patents

RNAi-prober som malsoker cancer-relaterte proteiner

Info

Publication number
NO20051423L
NO20051423L NO20051423A NO20051423A NO20051423L NO 20051423 L NO20051423 L NO 20051423L NO 20051423 A NO20051423 A NO 20051423A NO 20051423 A NO20051423 A NO 20051423A NO 20051423 L NO20051423 L NO 20051423L
Authority
NO
Norway
Prior art keywords
cancer
igfbp
treatment
rnai
crush
Prior art date
Application number
NO20051423A
Other languages
English (en)
Other versions
NO334573B1 (no
Inventor
Martin Gleave
Maxim Signaevsky
Burkhard Jansen
Eliana Beraldi
Ioannis P Trougakos
Efstatjios S Gonos
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of NO20051423L publication Critical patent/NO20051423L/no
Publication of NO334573B1 publication Critical patent/NO334573B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

RNAi-sekvenser som er nyttig som terapeutika i behandlingen av cancere av ulike typer, som inkluderer prostatacancer, sarkomer slik som osteosarkom, nyrecellekarcinom, brystcancer, blærecancer, lungecancer, koloncancer, ovariccancer, anaplastisk stor cellelymfom og melanon; og Alzheimer's sykdom. Disse sekvensene målsøker klustrin, IGFBP-5, IGFBP-2, både IGFBP-2 og -5 samtidig, Mitf, og B-raf Oppfinnelsen tilveiebringer ytterligere anvendelsen av disse RNAi-sekvensene i behandlingen av cancere av ulike typer, som inkluderer prostatacancer, sarkomer slik som osteosarkom, nyrecellekarcinom, brystcancer, blærecancer, lungecancer, koloncancer, ovariecancer, anaplastisk stor cellelymfom og melanom; og Alzheimer's sykdom, og en fremgangsmåte for å behandle slike tilstander gjennom administrasjonen av RNA-molekylene med RNAi-aktivitet til et individ, som inkluderer et menneskelig individ med behov for slik behandling.
NO20051423A 2002-08-21 2005-03-17 RNA molekyler som formidler degradering eller blokkering av translasjon av mRNA som koder for klusterin, farmasøytisk sammensetning inneholdende denne samt anvendelse NO334573B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US47238703P 2003-05-20 2003-05-20
PCT/CA2003/001277 WO2004018676A2 (en) 2002-08-21 2003-08-21 Rnai probes targeting cancer-related proteins

Publications (2)

Publication Number Publication Date
NO20051423L true NO20051423L (no) 2005-05-20
NO334573B1 NO334573B1 (no) 2014-04-14

Family

ID=31950539

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20051423A NO334573B1 (no) 2002-08-21 2005-03-17 RNA molekyler som formidler degradering eller blokkering av translasjon av mRNA som koder for klusterin, farmasøytisk sammensetning inneholdende denne samt anvendelse
NO20121038A NO337130B1 (no) 2002-08-21 2012-09-14 RNAi-prober som målsøker cancer-relaterte proteiner, farmasøytisk sammensetning inneholdende disse og anvendelse derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20121038A NO337130B1 (no) 2002-08-21 2012-09-14 RNAi-prober som målsøker cancer-relaterte proteiner, farmasøytisk sammensetning inneholdende disse og anvendelse derav

Country Status (10)

Country Link
US (5) US8252918B2 (no)
EP (2) EP2263679B1 (no)
JP (4) JP4717633B2 (no)
KR (3) KR101238701B1 (no)
AU (1) AU2003258426B2 (no)
CA (2) CA2494766C (no)
IL (3) IL166658A (no)
NO (2) NO334573B1 (no)
NZ (1) NZ552872A (no)
WO (1) WO2004018676A2 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163254B1 (en) 1999-02-26 2008-01-30 The University of British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US20030158143A1 (en) 2002-01-17 2003-08-21 Martin Gleave Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US7285541B2 (en) * 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
CA2494766C (en) * 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
JP2005013221A (ja) * 2003-06-03 2005-01-20 Keio Gijuku Ｂｒａｆ発現抑制を利用した癌の治療
US20050019918A1 (en) * 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
AU2005223649A1 (en) * 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US20100098663A2 (en) * 2004-06-22 2010-04-22 The Board Of Trustees Of The University Of Illinois Methods of Inhibiting Tumor Cell Proliferation with FoxM1 siRNA
TWI585411B (zh) * 2004-07-23 2017-06-01 太平洋愛吉生技股份有限公司 檢測膀胱癌之尿液標記物
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
PT1814595E (pt) * 2004-11-23 2014-04-02 Univ British Columbia Tratamento de cancro com uma combinação de um agente que perturba a via de sinalização egf e um oligonucleótido que reduz os níveis de clusterina
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
JP2010517941A (ja) * 2007-01-16 2010-05-27 ザ バーナム インスティテュート フォー メディカル リサーチ 結腸直腸癌の治療のための組成物および方法
US8071752B2 (en) 2007-01-29 2011-12-06 City Of Hope Multi-targeting short interfering RNAs
WO2008109361A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc, Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US8217161B2 (en) * 2008-04-22 2012-07-10 Clemson University Research Foundation Methods of inhibiting multiple cytochrome P450 genes with siRNA
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2673363B1 (en) * 2011-02-11 2017-08-23 The Rockefeller University Treatment of angiogenesis disorders
JP2015512877A (ja) 2012-02-22 2015-04-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌を治療するためのクラステリン阻害剤とｅｇｆｒ阻害剤の併用
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
CN106282185B (zh) * 2016-08-18 2020-06-26 广州市锐博生物科技有限公司 一种用于抑制簇集蛋白基因表达的成套siRNA及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5736580A (en) * 1980-08-13 1982-02-27 Hitachi Ltd Protecting method for converter
EP0575518A1 (en) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US20020086386A1 (en) * 1997-03-04 2002-07-04 Kamb Carl Alexander B-catenin assays, and compositions therefrom
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
EP1163254B1 (en) 1999-02-26 2008-01-30 The University of British Columbia Trpm-2 antisense therapy
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
US7297684B1 (en) * 1999-07-19 2007-11-20 The University Of British Columbia Antisense therapy for hormone-regulated tumors
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1272630A2 (en) * 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
NZ524274A (en) * 2000-09-14 2004-10-29 Univ British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
HU230458B1 (hu) * 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20030158143A1 (en) 2002-01-17 2003-08-21 Martin Gleave Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
CA2494766C (en) * 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ

Also Published As

Publication number Publication date
WO2004018676A2 (en) 2004-03-04
KR101212512B1 (ko) 2012-12-26
IL197159A (en) 2016-11-30
KR101238701B1 (ko) 2013-03-05
IL197159A0 (en) 2011-07-31
CA2882443C (en) 2016-12-13
US20110009472A1 (en) 2011-01-13
US7820635B2 (en) 2010-10-26
US8252918B2 (en) 2012-08-28
US8759308B2 (en) 2014-06-24
WO2004018676A3 (en) 2004-08-12
EP1532249A2 (en) 2005-05-25
KR20110122883A (ko) 2011-11-11
US20040096882A1 (en) 2004-05-20
IL233352A0 (en) 2014-08-31
US7964717B2 (en) 2011-06-21
CA2882443A1 (en) 2004-03-04
US20120202873A1 (en) 2012-08-09
EP2263679A2 (en) 2010-12-22
EP2263679B1 (en) 2014-10-08
NZ552872A (en) 2007-11-30
US20080274996A1 (en) 2008-11-06
US9487777B2 (en) 2016-11-08
KR20100135335A (ko) 2010-12-24
NO337130B1 (no) 2016-01-25
IL166658A (en) 2014-11-30
NO20121038L (no) 2005-05-20
AU2003258426B2 (en) 2008-04-10
AU2003258426A1 (en) 2004-03-11
US20060178329A1 (en) 2006-08-10
JP5662766B2 (ja) 2015-02-04
JP2013150624A (ja) 2013-08-08
JP2011036267A (ja) 2011-02-24
KR20050042483A (ko) 2005-05-09
NO334573B1 (no) 2014-04-14
CA2494766A1 (en) 2004-03-04
JP4717633B2 (ja) 2011-07-06
CA2494766C (en) 2015-05-12
IL166658A0 (en) 2006-01-15
JP5171887B2 (ja) 2013-03-27
EP2263679A3 (en) 2011-10-12
JP2010193908A (ja) 2010-09-09
JP2006500958A (ja) 2006-01-12
KR101117673B1 (ko) 2012-03-07

Similar Documents

Publication Publication Date Title
NO20051423L (no) RNAi-prober som malsoker cancer-relaterte proteiner
Cassidy et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial
Crino et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
Jhaveri et al. Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.
Ganesan et al. Epidermal growth factor receptor P753S mutation in cutaneous squamous cell carcinoma responsive to cetuximab-based therapy
Ho et al. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis
Ross et al. Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma.
Ellis et al. Advanced neuroendocrine prostate tumors regress to stemness
O'Hara et al. Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer.
Yu et al. L1 cell adhesion molecule as a therapeutic target in cancer
Jiang et al. The expression of protease-activated receptors in esophageal carcinoma cells: the relationship between changes in gene expression and cell proliferation, apoptosis in vitro and growing ability in vivo
Nugent et al. Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer
Blumenberg Human Skin Cancers: Pathways, Mechanisms, Targets and Treatments
WO2002020848A3 (en) Gene and sequence variation associated with cancer
Kara et al. A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
Krishnamurthy et al. A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
Ramlau et al. Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study.
Malik et al. Phase I study of RX-0201 in patients with advanced or metastatic solid tumors
Krebs et al. Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
TW200502247A (en) Genes and polypeptides relating to human colon cancers
Kim et al. Detection of ovarian cancer-specific gene by differentially expressed gene polymerase chain reaction prescreening and direct DNA sequencing
Boynton CXCR4 is involved in multiple functions of cancer cells and is a compelling target for monoclonal antibody-based therapeutics
Zieker et al. Effect of changes in the glycolytic metabolism on tumor progression and dissemination in gastric cancer.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees